Blood Test Predicts Multiple Sclerosis Worsening up to Two Years in Advance

Patients with multiple sclerosis showing increased levels of NfL, a nerve damage marker, in their blood tests are likely to experience a decline in their physical abilities within the next one to two years, according to a new study spearheaded by researchers at UC San Francisco.  
 
The study is the first to quantify the timeframe preceding disability worsening in which injury to the central nervous system takes place, said co-first author Ahmed Abdelhak, MD, of the UCSF Department of Neurology and the Weill Institute for Neurosciences. 

MS Prevalence and Symptomatology

Almost 1 million Americans suffer from MS. In advanced cases, patients may have limited mobility and experience spasticity, weakness, poor coordination, and incontinence. However, recent advances suggest that more severe symptoms can be substantially delayed or even averted. 
 
“This rising of NfL up to two years before signs of disability worsening, represents the window when interventions may prevent worsening,” said Abdelhak.  
 
In the study, which was recently published in the journal JAMA Neurology, and co-led by University Hospital and University of Basel, in Switzerland, the researchers looked at the incidence of disability worsening, defined as six months or more of increased impairment reflected in a higher score on the Expanded Disability Status Scale. They distinguished between disability worsening with relapse, which involves residual symptoms or the return of old ones following relapse, and gradual progression of symptoms without relapse.  

91% at elevated risk of developing disability worsening

The researchers tracked data spanning a 10-year period from approximately 4,000 patient visits to UCSF, comprising the EPIC study, and from approximately 9,000 patient visits to multiple sites in Switzerland, comprising the SMSC study. Together, the two studies included almost 1,900 patients. Among those, 570 patients were identified with disability that continued to worsen, of which the majority were independent of relapses. 
 
Elevated NfL levels were associated with up to a 91% higher risk of worsening disability with relapse approximately a year later, and up to a 49% higher risk of worsening disability without relapse nearly two years later, the researchers found.  
 
“We think that NfL elevation occurs earlier in disability worsening without relapse,” said Abdelhak. This different pattern may indicate “a more prolonged process that decreases in intensity in advance of increased impairment,” said co-senior author Ari Green, MD, medical director of the UCSF Multiple Sclerosis and Neuroinflammation Center. “This aligns with the recognition that death of nerve cells is a slow process that builds toward permanent disability and means that interventions to protect nerve cells might have time to also stop disability,” he said. 
 
“In addition to the groundbreaking findings on the temporal relationship between NfL increases and gradual disease progression in MS, the study supports the important role of NfL as an early marker of nerve damage,” said co-senior author Jens Kuhle, MD, PhD, who led the Swiss cohort and is head of the Multiple Sclerosis Center at University Hospital and University of Basel, Switzerland. “Monitoring NfL levels might be able to detect disease activity with higher sensitivity than clinical exam or conventional imaging,” he said.  
 
Future investigation will look into therapies that can stop progression during this period of elevated NfL.  

Reference: “Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis” by Ahmed Abdelhak, Pascal Benkert, Sabine Schaedelin, W. John Boscardin, Christian Cordano, Johanna Oechtering, Kirtana Ananth, Cristina Granziera, Lester Melie-Garcia, Shivany Condor Montes, Alexandra Beaudry-Richard, Lutz Achtnichts, Frederike C. Oertel, Patrice H. Lalive, David Leppert, Stefanie Müller, Roland G. Henry, Caroline Pot, Amandine Matthias, Anke Salmen, Jorge R. Oksenberg, Giulio Disanto, Chiara Zecca, Marcus D’Souza, Renaud Du Pasquier, Claire Bridel, Claudio Gobbi, Ludwig Kappos, Stephen L. Hauser, Bruce A. C. Cree, Jens Kuhle, Ari J. Green, UCSF, MS EPIC, and the SMSC Study Teams, Sergio Baranzini, Riley Bove, Michael Wilson, Jill Hollenbach, Refujia Gomez, Adam Santaniello, Meagan Harms, Tiffany Cooper, Stacy Caillier, Johannes Lorscheider, Alessandro Cagol, Muhamed Barakovic, Riccardo Galbusera, Özgür Yaldizli, Suvitha Subramaniam, Annette Orleth, Tobias Derfuss, Aleksandra Maleska Maceski, Eline Willemse, Lars G Hemkens, Perrine Janiaud, Lilian Demuth, Bettina Fischer-Barnicol, Robert Hoepner, Andrew Chan and Oliver Findling, 6 November 2023, JAMA Neurology.
DOI: 10.1001/jamaneurol.2023.3997

The study was funded by Westridge Foundation Grants from F. Hoffmann-La Roche, Fishman Family, grant 320030-160221 from the Swiss National Research Foundation, grant R35NS111644 from the NIH/NINDS, the Valhalla Foundation. The UCSF MS biorepository is supported by grant Si-2001- 375 35701 from the National MS Society.